0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover0.00%IV-133.92%PremiumJul 19, 2024Expiry Date11.45Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
$Summit Therapeutics(SMMT.US)$
Lung cancer Pharma company's new drug shows tangible improvement over the only other medication for the most common deadly case of lung cancer.
Fundamentals are solid. The PCB is overbought, though. We set our target for $13, but gonna watch this one close. Pharma be fickle.
$A10 Networks(ATEN.US)$
I feel is strongest of the day. They make software for things like data-center optimization. Wonde...
SMMT sank to as low as $7.26 intraday, down 17.9% on the session and 35.5% from its $11.25 intraday peak last Thursday.
Summit had rallied 284% intraday last Thursday, rising to as high as $11.25...
The largest climber on the S&P 500 and Nasdaq 100 was $Old Dominion Freight Line(ODFL.US)$, climbing 6%.
$Bath & Body Works(BBWI.US)$ was the highest decliner on the S&P, down 10% after the firm announced Q1 earnings, and projected a 2% drop in sal...
Larger Image: tradingview.com...
$Summit Therapeutics(SMMT.US)$
Summit Therapeutics - Received & Accepted Unsolicited Offer From Institutional Investor to Purchase 22.2 Mln Shares of Co's Common Stock at $9.00 per Share
$Summit Therapeutics(SMMT.US)$
$Jayud Global Logistics Ltd.(JYD.US)$
Ivonescimab Manuscript for Harmoni-a Clinical Trial Results Published in Jama—-Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant. it is original investigation, just published in JAMA.
No comment yet